Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 May 2020

Calles Antonio, Riess Jonathan W, Brahmer Julie R

Abstract excerpt

Immune checkpoint blockade with PD-(L)1 antibodies has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Similarly, the identification and targeting of oncogene drivers in metastatic NSCLC has dramatically improved patient outcomes with an expanding list of potentially actionable alterations and targeted therapies. Many of these molecular aberrations are more common in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 32421452
DOI: 10.1200/EDBK_280795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.PMID 32421452Read ↗

First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.Semantic proximity Read ↗

NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.Semantic proximity Read ↗

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung CancerSemantic proximity Read ↗

Immunotherapy in non-small cell lung cancer harbouring driver mutations.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

Identification of driver mutations in lung cancer: first step in personalized cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?Semantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.